Eve Elizabeth Slater
Director/Board Member chez STEALTH BIOTHERAPEUTICS CORP
Profil
Eve Elizabeth Slater is currently a Director at New England Healthcare Institute.
She is also an Independent Director at Stealth BioTherapeutics Corp.
since 2020 and a Professor at Columbia University College of Physicians & Surgeons since 2015.
In her former positions, Dr. Slater served as a Director at Vertex Pharmaceuticals, Inc. from 2004 to 2007.
She was also an Independent Director at Idera Pharmaceuticals, Inc. from 2011 to 2016.
Additionally, she held director positions at iTherX Pharmaceuticals, Inc., VaxGen, Inc., AnorMED, Inc., Phase Forward, Inc., and Innoviva, Inc. She was a Senior Vice President-Worldwide Policy at Pfizer Inc. from 2007 to 2009 and Assistant Secretary, Head-Health & Human Services at Health from 2001 to 2003.
Prior to that, she was a Senior Vice President-External Policy at Merck Research Laboratories Massachusetts LLC from 1983 to 2001.
Dr. Slater completed her undergraduate degree at Vassar College and obtained a doctorate from Columbia University College of Physicians & Surgeons.
Postes actifs de Eve Elizabeth Slater
| Sociétés | Poste | Début |
|---|---|---|
| STEALTH BIOTHERAPEUTICS CORP | Director/Board Member | 04/12/2020 |
| Columbia University College of Physicians & Surgeons | Corporate Officer/Principal | 01/01/1983 |
New England Healthcare Institute
 New England Healthcare Institute Miscellaneous Commercial ServicesCommercial Services New England Healthcare Institute operates as a national nonprofit, nonpartisan organization composed of stakeholders from across all key sectors of health and health care. The company was founded by Henri A. Termeer in 2002 and is headquartered in Boston, MA. | Director/Board Member | - |
Anciens postes connus de Eve Elizabeth Slater
| Sociétés | Poste | Fin |
|---|---|---|
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Director/Board Member | 13/06/2016 |
| PFIZER, INC. | Corporate Officer/Principal | 01/06/2009 |
| VERTEX PHARMACEUTICALS INCORPORATED | Director/Board Member | 01/08/2007 |
VaxGen, Inc.
 VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Director/Board Member | 01/08/2007 |
| INNOVIVA, INC. | Director/Board Member | 31/07/2007 |
Formation de Eve Elizabeth Slater
| Vassar College | Undergraduate Degree |
| Columbia University College of Physicians & Surgeons | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| INNOVIVA, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
iTherX Pharmaceuticals, Inc.
 iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services iTherX is a clinical stage pharmaceutical company focused on the discovery and development of innovative treatments for Hepatitis C. This is a disease that affects almost 3% of the world's population, and is the major cause of chronic liver disease, cirrhosis, liver failure and primary liver cancer. Currently there is only a single mode of therapy and less than 5% of patients can be successfully treated. The company continues to carry out focused research in their areas of expertise to provide sustainability of product pipelines. In an era of managed care and increased regulatory scrutiny, it is easy to yield to the temptation of producing 'me too drugs'. However, they think that innovation in the development of pharmaceutical products is important because it is the only way to improve the outcomes for patients. As such, they also think that innovation can ensure the financial returns that investors in health care deserve for the risks that they take. Their innovative approach is evident in their pipeline of Hepatitis C drug candidates. As new and better treatments are being sought, most companies involved in this effort are targeting the enzymes responsible for viral replication: polymerases and proteases. While these are important targets, there is a great deal of duplication of effort in these initiatives. At iTherX, they are pioneering the development of a novel class of HCV antivirals by targeting the steps involved in the entry of the hepatitis C virus into liver cells. Their Host Cell Receptor Target Program engenders small molecule compounds that target a liver cell membrane protein, SR-B1, which recognize and dock the virus. Their lead compound, ITX5061, has extensive safety data in over 250 patients, and shows picomolar potency in inhibiting HCV infection in vitro. They plan to initiate a Phase 2a clinical trial in HCV patients in Q2 of 2009. They have also used medicinal chemistry to develop back-up compounds for this program, and a clinical candidate has been selected for development. Another innovative program is novel cell receptor, which develops antagonists (including biologics) against a novel liver cell membrane protein required for infectivity of the virus. | Distribution Services |
VaxGen, Inc.
VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
AnorMED, Inc.
 AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | Health Technology |
Phase Forward, Inc.
 Phase Forward, Inc. Packaged SoftwareTechnology Services Phase Forward, Inc. developed e-process software solutions for accelerating global pharmaceutical development. The company was founded by Paul A. Bleicher and Augustine in 1997 and was headquartered in Waltham, MA. | Technology Services |
Health
 Health Movies/EntertainmentConsumer Services Part of Warner Bros. The private company is based in New York, NY. Discovery, Inc., Health is a renowned source for evidence-based health and wellness information. For over 40 years, Health has helped millions of readers cut through medical jargon, providing information in an easy-to-understand and culturally competent way to help readers take the next step in their health. Health is the trusted source for all things relating to wellness, offering solid, science-backed advice on physical and mental health, exercise, skin care and beauty, nutrition, and much more, empowering its wide, multi-generational audience of more than 18 million across platforms. Additional information can be found at health.com. | Consumer Services |
New England Healthcare Institute
New England Healthcare Institute Miscellaneous Commercial ServicesCommercial Services New England Healthcare Institute operates as a national nonprofit, nonpartisan organization composed of stakeholders from across all key sectors of health and health care. The company was founded by Henri A. Termeer in 2002 and is headquartered in Boston, MA. | Commercial Services |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
Stealth BioTherapeutics Corp.
 Stealth BioTherapeutics Corp. BiotechnologyHealth Technology Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Needham, MA. | Health Technology |
